ABCAM Plc (ABC) - AGM Statement
RNS Number : 2213P
22 October 2012
22 October 2012
("Abcam" or the "Company")
Result of AGM
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein
research tools,announces that all resolutions put to its Annual General
Meeting held earlier today were duly passed.
At the meeting, Michael Redmond, Abcam's Chairman, thanked Prof Tony
Kouzarides, a co-founder of the Company and a Non-Executive Director for 14
years, who, as previously announced, stepped down from the Board at the close
of the Annual General Meeting.
Michael Redmond, Abcam's Chairman, said: "I would like to thank Tony, on
behalf of everyone at Abcam, for the immense contribution he has made, playing
a vital role in the Company's success. We wish him well for the future."
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
Numis Securities - Nominated Advisor and Joint Broker + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Advisor
James Black - Corporate Broking
Peel Hunt LLP - Joint Broker + 44 (0) 207 418 8900
Andy Crossley - Corporate Broking
Buchanan + 44 (0) 20 7466 5000
Mark Court / Fiona Henson / Sophie Cowles
Notes for editors
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools.
These tools enable life scientists to analyse components of living cells at
the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK),
Cambridge, MA (USA), Eugene, OR (USA), San Francisco, CA (USA), Tokyo (Japan),
Hangzhou and Hong Kong (both in China), allowing it to serve a global customer
base in over 130 countries. Abcam employs over 600 staff across its eight
Abcam now has an online catalogue of more than 98,000 products sourced from
more than 400 suppliers. The catalogue includes a growing range of non-primary
antibody products such as secondaries, proteins, peptides, lysates,
immunoassays and other kits. Products are available for life science research
and distributed to academic and commercial users. A highly developed eCommerce
platform, which includes regional websites for the Chinese and Japanese
markets, allows customers to access up-to-date and detailed technical product
data sheets at the Company's website, www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol
ABC. The Company's vision is to be the world's leading life science reagents
This information is provided by RNS
The company news service from the London Stock Exchange
AGMBKBDQBBDDBKB -0- Oct/22/2012 12:52 GMT
Press spacebar to pause and continue. Press esc to stop.